CUE vs ED · rev $9.3M vs P/E 18, rev $15.26B
Cue Biopharma (CUE) versus Consolidated Edison Inc (ED) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Consolidated Edison Inc (ED) is a utilities - regulated electric company listed on US.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported ED revenue for 2024-12-31 was $15.26B. Net income was $1.82B. Revenue was up 4.0% from 2023-12-31 to 2024-12-31. ED currently screens at market cap $36.02B and trailing P/E 18.3.
CUE currently screens at market cap $59.5M. ED currently screens at market cap $36.02B and trailing P/E 18.3.
Not investment advice. Open the CUE and ED stock pages for the full models.
Not investment advice.